Drug Profile

OBP 401

Alternative Names: OBP-401; TelomeScan™ - Oncolys BioPharma

Latest Information Update: 08 Sep 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Oncolys BioPharma; Osaka University
Developer Oncolys BioPharma
Class Diagnostic agents; Imaging agents; Oncolytic viruses
Mechanism of Action Diagnostic imaging enhancers

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase I Solid tumours

Most Recent Events

02 Sep 2026 Phase-I clinical trials in Solid tumours (Diagnosis) in Japan (Intraperitoneal) (Oncolys BioPharma pipeline, September 2026)
30 Jun 2026 Clinical development is ongoing in Japan
28 Apr 2026 No recent reports of development identified for clinical-Phase-Unknown development in Cancer(Diagnosis) in Japan (Intraperitoneal)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com